Floatz logo

Sulanemadlin

Myelosuppression, Non-Human Animal

Aileron Therapeutics, Inc.protein_peptidePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Myelosuppression, Non-Human Animal cohort.

Asset / SponsorPhaseRating
Trilaciclib
The First Affiliated Hospital of Xiamen University
Phase 2B
Docetaxel
The First Affiliated Hospital of Xiamen University
Phase 2B
Myelo001
Myelo Therapeutics GmbH
Phase 2B
Sacituzumab Tirumotecan
The First Affiliated Hospital of Xiamen University
Phase 2CCC
Empegfilgrastim
Moscow Clinical Scientific Center
UnknownD

Same molecule, other indications

Sulanemadlin is also rated in:

lymphomaDormant
CC
Indicative · Phase 1/2
47 / 100
View asset →
medulloblastoma SHH activated and TP53 wild-typeDormant
CC
Indicative · Phase 1
46 / 100
View asset →
neoplasmDormant
CC
Indicative · Phase 1/2
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →